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 Performances of five commercial ELISA (EDI, AnshLabs, Dia.Pro, NovaTec, and Lionex) 
for detecting anti-SARS-CoV-2 IgG was evaluated  
 Samples used in this study are from diverse national background and the negative group 
contains samples that are seropositive for all other HCoV  
 All assays showed low sensitivity during the early stages (≤7 from symptom onset); 
however, it was greatly improved overtime   
 Lionex showed the highest specificity (98.6%), followed by EDI and Dia.Pro (97.1%,), 
NovaTec (85.7%), and AnshLabs (75.7%) 
 Lionex, which measures antibodies to the S1 protein, demonstrated the best performance 












Objectives: To evaluate and compare the performances of five commercial ELISA assays (EDI, 
AnshLabs, Dia.Pro, NovaTec, and Lionex) for detecting anti-SARS-CoV-2 IgG. Methods: 70 
negative control samples (collected before the COVID-19 pandemic) and samples from 101 RT-
PCR-confirmed SARS-CoV-2 patients (collected at different time points from symptoms onset: 
≤7, 8-14, and >14 days) were used to compare the sensitivity, specificity, agreement, positive and 
negative predictive values of each assay with RT-PCR. A concordance assessment between the 
five assays was also conducted. Cross-reactivity with other HCoV, non-HCoV respiratory viruses, 
non-respiratory viruses, and nuclear antigens was investigated. Results: Lionex showed the 
highest specificity (98.6%, 95%CI: 92.3-99.8), followed by EDI and Dia.Pro (97.1%, 95%CI: 
90.2-99.2), NovaTec (85.7%, 95%CI: 75.7-92.1), then AnshLabs (75.7%, 95%CI: 64.5-84.2). All 
ELISA kits cross-reacted with one anti-MERS IgG positive sample except Lionex. The sensitivity 
was low during the early stages of the disease but improved over time. After 14 days from 
symptoms onset, Lionex and NovaTec showed the highest sensitivity at 87.9% (95%CI: 72.7-95.2) 
and 86.4% (95%CI: 78.5-91.7), respectively. The agreement with RT-PCR results based on 
Cohen’s kappa was as follows: Lionex (0.89)> NovaTec (0.70)> Dia.Pro (0.69)> AnshLabs 
(0.63)> EDI (0.55). Conclusion: The Lionex ELISA, which measures antibodies solely to the S1 
protein, demonstrated the best performance.  
Key Words: COVID-19; SARS-CoV-2; serology; IgG; ELISA; sensitivity; specificity 
1. Introduction  
Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 










public health concern all over the world [1, 2]. As of July 1, 2020, the virus has caused more than 
10 million confirmed infections and over 500,000 reported deaths [3]. Currently, real-time reverse-
transcription polymerase chain reaction (RT-PCR) testing is the main technique used for the 
diagnosis of SARS-CoV-2 infection. However, false-negative RT-PCR results could occur in up 
to 30% of COVID-19 patients [4-6]. The reasons for this include poor sample collection 
techniques, sample collection too late after infection, or disease progression into the lower 
respiratory tract. Once an individual has been infected for at least seven days, the detection of 
antibodies is possibly more sensitive than RT-PCR for the diagnosis of COVID-19 [7]. Specific 
antibodies against SARS-CoV-2 can be detected as early as 4-7 days in approximately 40% of 
COVID-19 patients, with seroconversion rates reaching more than 90% by day 14 [7]. Therefore, 
serology could be used as a complementary test to RT-PCR to improve the diagnostic sensitivity, 
particularly in suspected COVID-19 individuals with negative RT-PCR results or those with no 
respiratory sample collected during the acute phase of illness [1, 2].  
Serology testing also has other advantages: it is easy to perform and interpret results; it is 
cheaper and quicker than RT-PCR; it indicates the patient immune status and infection stage (sero-
survey studies); it facilitates the selection of the best candidate donors (with the highest antibody 
titers) for plasma exchange, and it aids in assessing the efficacy of vaccines that are in 
development. Due to urgency and demand in the current crisis, a large number of commercial 
serological tests have been developed and introduced into the global market, but often with 
insufficient validation on clinical samples. Hence, there is a pressing need for identifying reliable 
immunoassays with high sensitivity and specificity for serology testing and surveillance of SARS-
CoV-2 infection as there remain persistent concerns regarding the accuracy and reliability of the 










In order to address this challenge, the present study evaluated the performance of five 
commercial CE-marked ELISA kits for detecting anti-SARS-CoV-2 IgG antibodies in samples 
from RT-PCR-confirmed COVID-19 patients. The sensitivity, positive predictive value, negative 
predictive value, positive percent agreement and Cohen’s kappa were measured for each assay 
using samples collected from SARS-CoV-2 RT-PCR-positive patients at different times from 
symptoms onset (≤7, 8-14, >14 days). The specificity and cross-reactivity were evaluated using 
pre-pandemic serum samples collected from healthy blood donors. A concordance assessment was 
conducted to compare the agreement between the kits.  
2. Methods  
2.1 Study design, ethical compliance, and sample collection 
We evaluated the performance of five CE-marked ELISA assays (EDI, Dia.Pro, AnshLabs, 
NovaTec, and Lionex) for detecting anti-SARS-CoV-2 IgG antibodies. The performance was 
assessed using anonymous samples collected from RT-PCR-confirmed SARS-CoV-2 patients 
admitted to Hamad Medical Corporation (HMC), the main public healthcare provider and the 
nationally designated provider for COVID-19 healthcare needs, with different COVID-19 clinical 
outcomes. For the negative control group, pre-pandemic serum samples collected from blood 
donors before 2019, were selected. The IRB approvals for this study were obtained from HMC 
(HMC-IRB# MRC-01-20-145, HMC-IRB# MRC-05-003, and HMC-IRB# MRC-05-007) and 
Qatar University (QU-IRB # QU-IRB 804-E/17).  
2.2 Serum samples 
A total of 101 case serum samples were selected from RT-PCR-confirmed COVID-19 











convalescent samples collected from COVID-19-recovered patients by the Qatar Communicable 
Disease Center (CDC) at HMC (n=21). Clinical records of the patients were reviewed to determine 
the time from symptoms onset to collection and categorized into three groups: Group: 1- less than 
or equal to 7 days; Group 2:  8-14 days; Group 3: more than 14 days. RNA was extracted from 
nasopharyngeal swab specimens using Qiagen extraction kit. The extracted RNA was tested for 
SARS-CoV-2 using the SuperscriptIII OneStep RT-PCR kit as recommended by the manufacture 
instruction (Cat No. 12594100, ThermoFisher, USA). Each sample was tested using three sets of 
primers targeting the E gene for screening and confirmed with two different sets of primers 
targeting the RdRp gene as described in [8]. CT values below 32 were considered positive. 
Characteristics of the 101 COVID-19 patients, including the demographic data and classification, 
are summarized in Table 1. The patients had a median age (IQR) of 48.0 (40.0-57.0), of which 
89.1% were males and 4.9% were females. Patients in the three-time points (≤7, 8-14, and >14 
days) had a median age of 50.0 (39.3-56.8), 49.0 (41.3-58.5), and 46.0 (34.3-55.5), respectively. 
For the control group, we utilized samples from healthy blood donors collected before 2019 
and used in previous studies [9-16]. The healthy blood donors had a median age of 36.0 (30.3-
45.0) with 82.9% males and 8.6% females. Details about the collection, transport, and storage 
methods of the control samples were described elsewhere [9-16]. The control group included 
samples that are seropositive for various viruses, including all other human coronaviruses (HCoV). 
Further details about the control samples can be found in Table 1 and S2.  
2.3 IgG ELISA kits 
Commercial ELISA kits from five different companies were used for the qualitative 











proteins in the sera of the COVID-19 patient group and control group. These kit are (i) Epitope 
Diagnostic (EDI™) novel coronavirus COVID-19 IgG (Ref. no. KT-1032, USA) (ii) AnshLabs 
SARS-CoV-2 IgG (Ref. no. AL-1001-I, USA), (iii) Diagnostic Bioprobes (Dia.Pro) COVID-19 
IgG (Ref. no. COV19G.CE, Italy (iv) NovaTec (NovaLisa®) SARS-CoV-2 IgG (Ref. no. 
COVG0940, Germany), and (v) Lionex COVID-19 ELISA-human IgG (Ref. no. LIO-COV19-
IgG, Germany). More details about the ELISA kits, including specifications, reported sensitivity, 
and specificity are shown in Table S2. All tests were carried out manually according to the 
manufacturers’ instructions. A microplate reader, Epoch 2 microplate spectrophotometer (Bio-
Tek, Italy) was used to read the optical density (OD) in all ELISA reactions. Borderline results 
were considered positive [1, 17]. 
2.4 Statistical analysis 
The sensitivity, specificity, positive predictive value, negative predictive value, positive 
percent agreement and Cohen’s Kappa were calculated to assess the performance of each assay 
with the positive SARS-CoV-2 RT-PCR patients [18, 19]. Specificity and cross-reactivity of each 
assay were assessed using the pre-pandemic control samples. Data were summarized by number 
and percentage of positive results for each assay. Borderline results were considered positive. 
Samples were categorized into three groups according to the time between collection and the onset 
of symptoms (≤7, 8-14, and >14 days), and all parameters were calculated for each group.  
Concordance assessment between the ELISA kits was conducted to assess the agreement between 
the kits. These concordance measures include overall, positive, and negative percent agreement, 
as well as Cohen’s kappa statistic. The latter measure is a standard and robust metric that estimates 
the level of agreement (beyond chance) between two diagnostic tests. Ranging between 0 and 1, a 











agreement, and a value  ≥0.75 denotes excellent agreement [20]. The significance level was 
indicated at 5%, and a 95% confidence interval (CI) was reported for each metric. All calculations 
were performed using Microsoft Excel 2016. Chi-square test was used to calculate the significance 
between the performances of ELISA kits. Significance (*) = p < 0.05; (**) = p < 0.01; (***) = p 
< 0.001. Further details about the statistical analysis and calculations can be found in Table S4.  
3. Results  
3.1 Diagnostic assessment of the IgG ELISA kits according to the time of sample collection 
after symptoms onset (n=101) 
The diagnostic assessment of all ELISA kits according to each time-point after symptoms 
onset (≤7 days, 8-14 days, >14 days) is summarized in Table 2 and Figure 2.  
In the first week of symptoms onset (≤7 days), the sensitivity (95% CI) ranged from 57.1% 
(39.1-73.5) to 78.6% (60.5-89.8) for EDI and AnshLabs, respectively. The highest positive and 
negative predictive values were estimated at 95.0% (76.4-99.1) for Lionex, and 89.8% (79.5-95.3) 
for AnshLabs, respectively. The best agreement with RT-PCR was observed in Lionex with 89.8% 
(82.2-94.4) positive percent agreement and Cohen kappa index of 0.73 (0.63-0.82). The lowest 
agreement was observed in AnshLabs with 76.5% (67.2-83.8) positive percent agreement and a 
kappa index of 0.49 (0.36-0.61).  
In the second week of symptoms onset (8-14 days), all parameters increased compared to 
the first week, where the highest sensitivity was scored by AnshLabs at 90.0% (77.0-96.0). The 
highest positive and negative predictive values were estimated at 97.1% (85.1-99.5) for Lionex 










observed in AnshLabs with 80.9% (72.6-87.2) positive percent agreement and a kappa index of 
0.61 (0.51-0.72), while the highest agreement was scored Lionex with 92.7% (86.3-96.3) positive 
percent agreement and a kappa index of 0.84 (0.77-0.91).  
The performance of the evaluated IgG ELISA kits varied after 14 days of symptoms onset. 
Compared to the second week, the sensitivity decreased in EDI, AnshLabs, and Dia.Pro down to 
60.6% (43.7-75.3), 84.8 (69.1-93.4), and 66.7% (49.6-80.3), respectively (Figure 2). However, the 
sensitivity slightly increased for NovaTec and Lionex, where both assays showed the highest 
sensitivity at 87.9% (72.7-95.2). Also, Lionex showed the highest positive and negative predictive 
values at 96.7% (83.3-99.4), and 94.5% (86.7-97.9), respectively. The positive percent agreement 
of EDI, AnshLabs, and Dia.Pro also slightly dropped to 85.4% (77.4-91.0), 78.6% (69.8-85.5), 
and 87.4% (79.6-92.5), respectively. Whilst no change was observed in the positive percent 
agreement of NovaTec, it slightly increased in Lionex to 95.1% (89.1-97.9) with a Kappa index of 
0.89 (0.82-0.95).  
3.2 Assays specificity according to the negative control subgroups (n=70) 
All assays showed acceptable overall specificity ranging from 85.7-98.6%, except 
Anshlabs which had a 75.7% (53/70; 64.5-84.2) specificity. Lionex showed the highest specificity 
at 98.6% (69/70; 92.3-99.8), followed by EDI and Dia.Pro at 97.1% (68/70; 90.2-99.2), and then 
NovaTec with 85.7% (60/70; 75.7-92.1) specificity (Table 3 and Figure 1). The specificity of each 
kit in relation to sample cross-reactivity with other viruses (Table 3 and S1) was also calculated. 
All assays cross-reacted with other human coronaviruses (HCoVs), except Lionex, which had a 
100% specificity (20/20; 83.9-100) in this sub-group. AnshLabs, NovaTec, and Dia.Pro showed 











of 60.0% (9/15; 35.8-80.2), 73.3% (11/15; 48.1-89.1), and 93.3% (14/15; 70.2-98.8), respectively. 
Only EDI and Lionex did not show cross-reactivity with non-HCoV respiratory viruses with 100% 
(15/15; 79.6-100) specificity for this subgroup. All assays showed some cross-reactivity with non-
respiratory viruses except Dia.Pro, which had 100% (33/33; 93.9-100) specificity. Finally, all 
assays showed no cross-reactivity with antinuclear antibodies samples except AnshLabs, which 
cross-reacted with one control sample [50.0% (1/2; 9.5-90.6)]. However, the sample size was very 
small, as only two specimens were positive for antinuclear antibodies were used. 
3.3 Concordance assessment between IgG ELISA kits   
Table 4 shows the concordance assessment between the different IgG ELISA kits. The 
overall percent agreement ranged from 79.5% (72.9-84.9) for AnshLabs/EDI test combination and 
97.1% (93.3-98.8) for Dia.Pro/EDI test combination. The positive percent agreement ranged from 
66.0% (56.4-74.4) for EDI vs. AnshLabs and Dia.Pro vs. AnshLabs to 100% (94.7-100) for 
AnshLabs vs. EDI, NovaTec vs. EDI, and NovaTec vs. Dia.Pro. The negative percent agreement 
ranged from 65.7% (56.1-74.2) for AnshLabs vs. Dia.Pro to 100% (95.4-100) for EDI vs. NovaTec 
and Dia.Pro vs. NovaTec, and also 100% (94.7-100) for EDI vs. AnshLabs. Importantly, Cohen’s 
Kappa statistic denoted fair/good to excellent agreement and ranged between 0.59 (0.51-0.68) for 
AnshLabs/Dia.Pro test combination and 0.94 (0.90-0.98) for Dia.Pro/EDI test combination.  
4. Discussion 
In this study, we evaluated the performances of five CE-marked ELISA kits using 101 
samples collected from SARS-CoV-2 RT-PCR-confirmed patients and 70 pre-pandemic control 
samples collected from healthy blood donors. The sensitivity, specificity, agreement, positive and 











14, >14 days) for each kit (Table 2). Also, the overall agreement and Cohen’s kappa were 
calculated to compare the assays (Table 4).  
Our results showed that most of the evaluated assays demonstrated a very good 
performance during the first week after symptoms onset compared to other studies [21-24]. 
Expectedly, the agreement between the outcome of each ELISA kit and RT-PCR increased with 
time after symptoms onset, consistent with a time lag between the onset of infection and the 
development of detectable antibodies. High rates of positive results were reached after the first 
week of clinical illness. This increase was observed with the sensitivity, positive and negative 
predictive values, positive percent agreement and Cohen’s Kappa (Table 2). Even though the 
sensitivity was lower during the early stages of the disease, it was greatly improved 8-14 days after 
symptoms onset. AnshLabs showed the highest sensitivity in patients tested within the first two 
weeks of symptoms onset (Figure 2). However, AnshLabs had the lowest specificity compared to 
the other kits. After 14 days of symptoms onset, the sensitivity slightly decreased in all assays, 
except NovaTec and Lionex. This could be because 63.6% (21/33) of the samples in this time point 
were collected by the CDC from recovered patients, who we do not have their clinical data, 
including the severity of the disease, whether they developed symptoms or not, and the exact day 
of sample collection. Hence, these patients might not have elicited enough antibody response to 
be detected by most of the assays (Table S4, group 3 sample No. 4, 11, 15, and 26). Surprisingly, 
one of the ICU-admitted patients did not show a detectable antibody response by all ELISA assays 
(Table S3, group 3 sample No.33), which needs further investigation by other highly sensitive 
assays. Typically, if borderline results were obtained in ELISA testing, another sample is taken 
from the patient 1-2 weeks later for re-testing. However, this was not possible here as we were 











samples were collected from RT-PCR-positive patients, borderline results were considered 
positive, consistent with similar studies [1, 17]. Interestingly, only one pre-pandemic sample with 
positive anti-MERS-CoV IgG antibodies was found positive by four ELISA kits (Table 3 and S3), 
except Lionex, which demonstrated the highest specificity at 98.6% (Figure 1). 
Another interesting finding is the heterogeneity of IgG antibody response in COVID-19 
patients. Most developed serology assays target either the spike (S) or the nucleocapsid (N) protein 
of SARS-CoV-2. Previous studies performed on other HCoV suggested that the anti-nucleocapsid 
(anti-N) antibody response may appear earlier than the anti-spike (anti-S) response and may wane 
more rapidly [25, 26]. Here, we expect that the differences in sensitivity between ELISA kits 
depend on the targeted protein used in each assay. We noticed that there was a decline in the 
sensitivity of the ELISA kits targeting the N protein. However, the sensitivity increased in the kit 
that solely targets the S1 protein (Lionex). Therefore, a possible explanation for this is that the 
level of anti-N and anti-S antibodies may be similar during the acute phase of COVID-19 illness, 
but anti-N antibodies could be waning after the second week [25, 26]. Moreover, this could also 
explain the high specificity of Lionex compared to the other assays (Figure 1). That is, Lionex 
targets the S1 protein, which is smaller and less conserved across different families of viruses than 
the N protein. Therefore, detection of anti-N antibodies may be useful in distinguishing more 
recent antibody response, while anti-S antibody may be used during the early and convalescent 
phases. Still, this does not explain why the sensitivity of NovaTec, which targets the N protein, 
remained steady after the second week compared to EDI which also targets the same protein (N).  
Concordance assessment between the different assays showed good to excellent agreement 
between the kits. EDI and Dia.Pro had the best overall agreement (97.1%) and kappa index (0.94). 











despite having a very high specificity (97.1%). Therefore, for diagnosis and clinical relevance, 
these two assays are the least recommended for such purposes. NovaTec and AnshLabs also 
showed an excellent positive percent agreement (91.2%) and a kappa index (0.82), where both 
assays had comparable overall sensitivity and specificity. Lionex, however, showed a variation in 
the agreement with the other ELISA kits, which could be due to the fact that Lionex is the only kit 
that targets S1 protein.  
From an epidemiological perspective, the high sensitivity of the assay in combination with 
robust specificity is desirable. Here, Lionex and NovaTec ELISA kits showed the best overall 
performance in terms of specificity, sensitivity, agreement with RT-PCR, positive and negative 
predictive values compared to the other assays. The overall performance of both NovaTec and 
Lionex IgG manual ELISA was comparable to other detection methods, including automated tests, 
reported elsewhere [27, 28]. Both assays showed a diagnostic sensitivity of 87.9% after 14 days of 
symptoms onset compared to Abbott Architect (84.2%) and Cobas 6800 systems (95.2%). The 
specificity of Lionex (98.6%) was also comparable to the aforementioned automated assays (100% 
and 99.3%, respectively) [27, 28]. 
A strength of this study is the use of a diverse control group to evaluate cross reactivity 
with antibodies against various viruses, including MERS, SARS-CoV, endemic coronaviruses, 
respiratory viruses, and other viruses. One of the limitations of this study is that the clinical details 
of the patients were not available which are important to understand why some of them did not 
develop an antibody response that is detectable by the evaluated kits. It would be very beneficial 
to perform a new study using a large sample size collected from patient with known disease 
severity outcomes. For instance, critical, severe, moderate, mild and asymptomatic to have a better 











In conclusion, we believe that two ELISA kits (NovaLisa, and Lionex) showed promising 
overall results which could be used in the future for clinical testing.  Further, all assays showed 
acceptable specificity ranging from 85.7-98.6%, except for the AnshLabs ELISA. Finally, 
although serological assays do not replace molecular tests in diagnosing active infection, they 
serve as an essential tool to accurately estimate the seroprevalence of SARS-CoV-2 in the general 
population and to quantify the level of herd immunity [29]. This could help ease the restrictions 
on human mobility and interactions without provoking a significant resurgence of transmission 
and mortality. However, it is still not clear whether positive results by serology reflect a protective 
immune response against infection [30]. Further studies are essential to distinguish functional 
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Figure 1: Comparison of overall sensitivity (n=101) and specificity (n=70) of each IgG ELISA. 
Figure 2: Proportion of samples testing positive for anti-SARS-CoV-2 IgG antibodies. Samples 
were stratified based on the time of collection after symptoms onset (≤7 days, n=28; 8-14 days, 












































































Comparison of senitivity of IgG ELISA kits in COVID-19 patients based on 
symptom onset interval



















≤7 days 8-14 days >14 days 
N 101 28 (27.7%) 40 (39.6%) 33 (32.7%) 70 











Gender      
Male 76 (89.1%) 25 (89.3%) 40 (100%) 11 (33.3%) 58 (82.9%) 
Female 4 (4.9%) 3 (10.7%) - 1 (3.0%) 6 (8.6%) 
N/A 21 (20.8%) - - 21 (63.6%) 6 (8.6%) 
Sample Source      
Hospitalized, non-
ICU patient 
45 (44.6%) 17 (60.7%) 23 (57.5%) 5 (15.2%) - 
ICU-admitted 
patient 
35 (34.7%) 11 (39.3%) 17 (42.5%) 7 (21.2%) - 
Recovered 
convalescent 
plasma donors  






















Table 2. The diagnostic assessment of the different commercial IgG ELISA according to time of sample collection after symptoms  
Days after symptoms 
onset   
ELISA Kit  
Sensitivity 
% (95% CI) 
Positive Predictive 
Value 
% (95% CI) 
Negative Predictive 
Value 
% (95% CI) 
Positive percent 
Agreement 
% (95% CI) 
Cohen's Kappa 
k (95% CI) 
≤7 days (n=28) 
EDI  57.1 (39.1-73.5) 88.9 (67.2-96.9) 85.0 (75.6-91.2) 85.7 (77.4-91.3) 0.61 (0.49-0.72) 
AnshLabs  78.6 (60.5-89.8) 56.4 (41.0-70.7) 89.8 (79.5-95.3) 76.5 (67.2-83.8) 0.49 (0.36-0.61) 
Dia.Pro  57.1 (39.1-73.5) 88.9 (67.2-96.9) 85.0 (75.6-91.2) 85.7 (77.4-91.3) 0.61 (0.49-0.72) 
NovaTec 64.3 (45.8-79.3) 64.3 (45.8-79.3) 85.7 (75.7-92.1) 79.6 (70.6-86.4) 0.50 (0.38-0.62) 
Lionex  67.9 (49.3-82.1) 95.0 (76.4-99.1) 88.5 (79.5-93.8) 89.8 (82.2-94.4) 0.73 (0.63-0.82) 
8-14 days (n=40) 
EDI  75.0 (59.8-85.8) 93.8 (79.9-98.3) 87.2 (78.0-92.9) 89.1 (81.9-93.7) 0.75 (0.67-0.84) 
AnshLabs  90.0 (77.0-96.0) 67.9 (54.5-78.9) 93.0 (83.3-97.2) 80.9 (72.6-87.2) 0.61 (0.51-0.72) 
Dia.Pro  72.5 (57.2-83.9) 93.5 (79.3-98.2) 86.1 (76.8-92.1) 88.2 (80.8-93.0) 0.73 (0.64-0.82) 
NovaTec 87.5 (73.9-94.5) 77.8 (63.7-87.5) 92.3 (83.2-96.7) 86.4 (78.7-91.6) 0.71 (0.62-0.81) 
Lionex  82.5 (68.1-91.3) 97.1 (85.1-99.5) 90.8 (82.2-95.5) 92.7 (86.3-96.3) 0.84 (0.77-0.91) 
>14 days (n=33) 
EDI  60.6 (43.7-75.3) 90.9 (72.2-97.5) 84.0 (74.5-90.4) 85.4 (77.4-91.0) 0.63 (0.53-0.74) 
AnshLabs  84.8 (69.1-93.4) 62.2 (47.6-74.9) 91.4 (81.4-96.3) 78.6 (69.8-85.5) 0.55 (0.44-0.67) 
Dia.Pro  66.7 (49.6-80.3) 91.7 (74.2-97.7) 86.1 (76.8-92.1) 87.4 (79.6-92.5) 0.69 (0.59-0.79) 
NovaTec 87.9 (72.7-95.2) 74.4 (58.9-85.4) 93.8 (85.0-97.5) 86.4 (78.5-91.7) 0.70 (0.60-0.80) 












EDI  65.3 (56.1-74.6) 97.1 (94.5-99.6) 66.0 (58.9-73.1) 78.4 (72.2-84.5) 0.58 (0.46-0.70) 
AnshLabs  85.1 (78.2-92.1) 83.5 (77.9-89.1) 77.9 (71.7-84.2) 81.3 (75.4-87.1) 0.61 (0.49-0.73) 
Dia.Pro  66.3 (57.1-75.6) 97.1 (94.6-99.6) 66.7 (59.6-73.7) 78.9 (72.8-85.1) 0.59 (0.48-0.71) 
NovaTec 81.2 (73.6-88.8) 89.1 (84.5-93.8) 75.9 (69.5-82.4)  83.0 (77.4-88.7) 0.66 (0.54-0.77) 












Table 3: The specificity of the five evaluated IgG ELISA kits according to the negative control subgroups (n=70).  
*MERS: middle east respiratory syndrome coronavirus, SARS-CoV: severe acute respiratory syndrome coronavirus, RSV: respiratory 
syncytial virus, HSV-1: herpes simplex virus 1, HSV-2 herpes simplex virus 2, HHV-6: human herpesvirus-6, HHV-8: human 
herpesvirus-8, EBV: Epstein-Barr virus, HBV: hepatitis B virus, HCV: hepatitis C virus, HEV: hepatitis E virus, HGV: hepatitis G 
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% (95% CI) % (95% CI) % (95% CI) k (95% CI) 
EDI 
AnshLabs  79.5 (72.9-84.9) 100 (94.7-100) 66.0 (56.4-74.4) 0.60 (0.52-0.69) 
Dia.Pro  97.1 (93.3-98.8) 97.1 (89.9-99.2) 97.1 (91.8-99.0) 0.94 (0.90-0.98) 
NovaTec 86.0 (80.0-90.4) 100 (94.7-100) 76.7 (67.7-83.8) 0.72 (0.65-0.80) 
Lionex 86.0 (80.0-90.4) 92.6 (83.9-96.8) 81.6 (73.0-87.9) 0.72 (0.64-0.79) 
AnshLabs 
EDI  79.5 (72.9-84.9) 66.0 (56.4-74.4) 100 (94.7-100) 0.60 (0.52-0.69) 
Dia.Pro  78.9 (72.2-84.4) 66.0 (56.4-74.4) 98.5 (92.1-99.7) 0.59 (0.51-0.68) 
NovaTec 91.2 (86.0-94.6) 87.4 (79.6-92.5) 97.1 (89.9-99.2) 0.82 (0.76-0.88) 
Lionex  80.7 (74.1-85.9) 73.8 (64.6-81.3) 91.2 (82.1-95.9) 0.62 (0.53-0.70) 
Dia.Pro 
EDI  97.1 (93.3-98.8) 95.7 (88.0-98.5) 98.0 (93.1-99.5) 0.94 (0.90-0.98) 
AnshLabs  78.9 (72.2-84.4) 98.6 (92.2-99.7) 65.7 (56.1-74.2) 0.59 (0.51-0.68) 
NovaTec 86.5 (80.6-90.9) 100 (94.7-100) 100 (95.4-100) 0.73 (0.66-0.81) 
Lionex  85.4 (79.3-89.9) 91.2 (82.3-96.0) 77.5 (68.4-84.5) 0.71 (0.63-0.78) 
NovaTec 
EDI  86.0 (80.0-90.4) 73.9 (64.1-81.8) 100 (95.4-100) 0.72 (0.65-0.80) 
AnshLabs  91.2 (86.0-94.6) 97.8 (92.4-99.4) 83.5 (73.9-90.1) 0.82 (0.76-0.88) 
Dia.Pro  86.5 (80.6-90.9) 75.0 (65.3-82.7) 93.3 (86.1-96.9) 0.73 (0.66-0.81) 












EDI  86.0 (80.0-90.4) 76.8 (66.6-84.6) 94.4 (87.5-97.6) 0.72 (0.64-0.79) 
AnshLabs  80.7 (74.1-85.9) 92.7 (84.9-96.6) 69.7 (59.5-78.2 0.62 (0.53-0.70) 
Dia.Pro  85.4 (79.3-89.9) 76.8 (66.6-84.6) 78.7 (69.1-85.9) 0.71 (0.63-0.78) 
NovaTec 83.6 (77.4-88.4) 89.0 (80.4-94.1) 88.6 (79.8-93.9) 0.67 (0.60-0.75) 
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